Thinly Traded, Big Potential: This Biotech’s Blood Test Proves Its Precision

Sponsored:

Monday, May 12, 2025

An under-the-radar biotech caught our attention today. While the company's news provides meaningful validation for its blood-based test, the stock trades thinly, limiting any immediate market reaction to key developments. Still, the story was too compelling for us to ignore.

BioMark Diagnostics Inc. (CSE: BUX) (OTCQB: BMKDF) announced this morning the publication of a landmark study in the International Journal of Molecular Sciences, validating the high specificity and accuracy of its blood-based test for early-stage non-small cell lung cancer (NSCLC). The research, titled “Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection,” demonstrated the effectiveness of BioMark’s metabolomics and machine learning technology in distinguishing lung cancer from a range of non-cancerous lung diseases, a critical challenge in early diagnosis.

The study analyzed 680 archived plasma samples in the discovery phase and validated findings with an independent set of 216 samples. A standout feature was the inclusion of a clinically complex control group comprising not just healthy individuals but also patients with various non-malignant lung conditions. This rigorous design ensured the test was assessed under real-world conditions. The models achieved over 93% AUROC for stage I–II NSCLC, underlining the strength and reliability of BioMark’s diagnostic approach, especially for early detection.

Company executives hailed the study as a major milestone toward clinical adoption. Dr. Jean-François Haince emphasized the importance of testing against complex cases to prove specificity, while CEO Rashid Ahmed Bux highlighted the publication as external validation of years of work. With current screening methods like low-dose CT scans often leading to false positives, BioMark’s minimally invasive blood test could offer a more accurate, patient-friendly alternative for early lung cancer detection and intervention.

As noted earlier, shares of BUX and its U.S. counterpart did not trade on the news—an unfortunate outcome considering the significance of the announcement.

Sponsored: